Compare Novo Nordisk A/S (NVO) vs Riot Platforms Inc (RIOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Riot Platforms Inc — how do they compare? Novo Nordisk A/S trades at $45.07 (market cap $200.69B), while Riot Platforms Inc trades at $21.83 (market cap $8.35B). The key difference: Novo Nordisk A/S is far larger — about 24× Riot Platforms Inc's market cap, and Novo Nordisk A/S pays a 3.98% dividend while Riot Platforms Inc pays none. Which is the better fit depends on your goals.
| NVO | RIOT | |
|---|---|---|
Market Cap | $200.69B | $8.35B |
Sector | Health | Technology |
52-Week High | $63.98 | $28.67 |
52-Week Low | $35.29 | $11.83 |
Enterprise Value | $215.49B | $8.76B |
Dividend Yield | 3.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.
The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.
RIOT Platforms trades at $22.26, up 2.11% today, with a bullish technical signal from moving averages. The stock shows strong analyst support with 94.7% buy ratings and a $33 consensus price target. Recent news highlights a transformative $9.1 billion AI data center deal with Anthropic, shifting focus from Bitcoin mining to high-margin AI infrastructure. However, fundamental challenges persist with negative net income margins and consecutive earnings misses.
The outlook balances significant AI-driven growth potential against current profitability concerns. The Anthropic partnership provides long-term revenue visibility but execution risks remain. With the stock trading near analyst price targets, upside depends on successful AI transition and improved financial performance. Key risks include competitive pressures, regulatory uncertainty, and continued cash flow challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →
